Proceeds will support advancement of the Company's oral small molecule

收益将支持公司口服小分子的进展。

GLP-1

GLP-1

candidate

候选人

and other novel cardiometabolic programs into clinical development

并将其他新型心代谢项目引入临床开发

BOULDER, Colo.

科罗拉多州博尔德

,

，

March 31, 2026

2026年3月31日

/PRNewswire/ -- Ambrosia Biosciences Inc. ('Ambrosia') today announced a $100 million oversubscribed Series B financing.

/PRNewswire/ -- Ambrosia Biosciences Inc.（“Ambrosia”）今天宣布完成了1亿美元的超额认购B轮融资。

The financing provides $100 million in committed capital, intended to fund the Company through clinical trial initiation of its oral small molecule

融资提供了 1 亿美元的承诺资本，旨在为公司提供资金直到其口服小分子的临床试验启动。

GLP-1

GLP-1

. The financing was co-led by new investors Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor..

融资由新投资者Blue Owl Healthcare Opportunities、Redmile和Deep Track Capital共同领投。现有投资者BVF Partners和Boulder Ventures也参与了投资，并加入了其他新投资者Janus Henderson Investors、Samsara BioCapital以及一位未披露的机构投资者。

Proceeds from the financing will support:

融资所得将用于支持：

Advancement of the Company's novel oral small molecule

公司新型口服小分子的进展

GLP-1

GLP-1

into a Phase 1 clinical trial

进入第一阶段临床试验

Continued development of the Company's other small molecule programs, including GIP and amylin

公司其他小分子项目的持续开发，包括GIP和艾米林

'This financing represents a strong endorsement of our team, science and pipeline, and reflects investor conviction in next-generation oral cardiometabolic therapies,' said Nick Traggis, Founder and Chief Executive Officer of Ambrosia. 'As the field moves beyond first-generation molecules, we see a meaningful opportunity for differentiated small molecule modulators that are designed with combinability in mind.

“这笔融资代表了对我们团队、科学和研发管线的强烈认可，并反映了投资者对下一代口服心代谢疗法的信心，”Ambrosia创始人兼首席执行官尼克·特拉吉斯表示。“随着领域超越第一代分子，我们看到了一个有意义的机会，可以开发出具有组合设计优势的差异化小分子调节剂。”

We appreciate the support of both new and existing investors and look forward to advancing our lead programs into the clinic.'.

我们感谢新老投资者的支持，并期待将我们的主导项目推进到临床阶段。

Ambrosia is developing a portfolio of orally bioavailable small molecules targeting key metabolic G-protein coupled receptors (GPCRs), including

Ambrosia 正在开发一系列针对关键代谢性 G 蛋白偶联受体 (GPCR) 的口服生物可利用小分子组合，包括

GLP-1

GLP-1

, GIP and amylin. By combining structural biology with advanced computational chemistry, the Company designs molecules with differentiated pharmacology to support both standalone therapies and strategic combinations for obesity and related cardiometabolic diseases.

，GIP 和胰淀素。通过将结构生物学与先进的计算化学相结合，该公司设计出具有差异化药理学的分子，以支持针对肥胖症及相关心脏代谢疾病的独立疗法和战略组合。

'With first-generation oral

‘第一代口服

GLP-1

GLP-1

therapies now approved, we believe Ambrosia is well positioned to develop differentiated small molecule therapies with best-in-class potential,' said Sara Clarke, Ph.D., Vice President, Blue Owl Capital. 'We are excited to lead such a strong syndicate of investors and to support the Ambrosia team as they advance their lead .

“随着现在疗法获得批准，我们相信Ambrosia有能力开发出具有最佳潜力的差异化小分子疗法，”蓝猫头鹰资本副总裁Sara Clarke博士说道。“我们很激动能够带领这样强大的投资者财团，并支持Ambrosia团队推进他们的领先项目。”

GLP-1

GLP-1

program, and broader small molecule pipeline, into the clinic.'

项目，以及更广泛的小分子管道，进入临床。'

In connection with the financing, Sara Clarke will join Ambrosia's Board of Directors.

与融资相关，Sara Clarke将加入Ambrosia的董事会。

About Ambrosia Biosciences Inc.

关于Ambrosia生物科学公司

Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. For more information, please visit

Ambrosia Biosciences Inc. 是一家私人持有的药物研发公司，专注于开发口服的小分子疗法以治疗肥胖症和其他代谢性疾病。欲了解更多信息，请访问

www.ambrosiabiosciences.com

www.ambrosiabiosciences.com

Forward-Looking Statement

前瞻性声明

This press release may contain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements. Words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'plan,' 'expect,' 'predict,' 'potential,' 'opportunity,' 'goals,' or 'should,' and similar expressions are intended to identify forward-looking statements..

本新闻稿可能包含涉及重大风险和不确定性的前瞻性陈述。本新闻稿中除历史事实陈述外的所有陈述均为前瞻性陈述。诸如“相信”、“可能”、“将”、“估计”、“继续”、“预期”、“打算”、“计划”、“期望”、“预测”、“潜力”、“机会”、“目标”或“应该”等词汇及类似表达旨在识别前瞻性陈述。

These forward-looking statements include, among others, statements regarding Ambrosia's goals and strategic plans. Such statements are based on management's current expectations and involve risks, uncertainties and assumptions. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.

这些前瞻性陈述包括但不限于关于Ambrosia的目标和战略计划的陈述。此类陈述基于管理层的当前预期，并涉及风险、不确定性和假设。由于多种因素，实际结果和表现可能与前瞻性陈述中预计的内容存在重大差异。

Moreover, Ambrosia operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make.

此外，Ambrosia 在一个竞争激烈且快速变化的环境中运营。新的风险不时出现。其管理层无法预测所有风险，也无法评估所有因素对其业务的影响，或任何因素或因素组合可能导致实际结果与公司可能做出的前瞻性陈述中包含的结果存在重大差异的程度。

Ambrosia undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement..

Ambrosia 没有义务修订或公开发布对任何前瞻性声明的修订结果，除非法律要求。鉴于这些风险和不确定性，提醒读者不要过分依赖此类前瞻性声明。所有前瞻性声明均受此警示性声明的全面约束。

Investor & Media Contact:

投资者和媒体联系：

Ambrosia Biosciences

琥珀生物科学

Andrea Flynn, Ph.D.

安德烈亚·弗林，哲学博士

Chief Business Officer

首席商务官

[email protected]

电子邮件地址

SOURCE Ambrosia Biosciences

来源：Ambrosia Biosciences

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示